Codiak BioSciences

📍 Cambridge, United States🗓 Founded 2015👥 53 employees💰 Last funded Oct 2015
Biotechnology Research🌐 codiakbio.com
Website LinkedIn
About Codiak BioSciences Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Codiak BioSciences?
Codiak BioSciences has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Codiak BioSciences last raise funding?
The most recent investment in Codiak BioSciences recorded on gritt.io was in October 2015.
When was Codiak BioSciences founded?
Codiak BioSciences was founded in 2015.
What industry is Codiak BioSciences in?
Codiak BioSciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Codiak BioSciences based?
Codiak BioSciences is headquartered in Cambridge, United States.